Brineura Delays CLN2 Onset, Progression in Case Study of 2 Siblings

Brineura Delays CLN2 Onset, Progression in Case Study of 2 Siblings

296961

Brineura Delays CLN2 Onset, Progression in Case Study of 2 Siblings

Two years of treatment with Brineura (cerliponase alfa) safely and effectively delayed the onset of late-infantile Batten disease in a 23-month-old boy who had not exhibited symptoms when he started treatment, a case study shows. The same treatment slowed disease progression in his older sister, who received the therapy after symptom onset at 47 months (nearly 4 years) of age. While preliminary, these findings suggest that Brineura can slow disease progression when late-infantile Batten disease,…

You must be logged in to read/download the full post.